clinical trial · NCT05251090
A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection
Jiangsu Gensciences lnc.·phase1·completed·n = 13
Hemophilia AADVATEFRSW107
brief summary
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection (FRSW107) Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in Severe Hemophilia A.
started
Jun 16, 2021
primary completion
Nov 15, 2021
completion
May 9, 2022
last updated
Aug 22, 2023
official title
A Phase I, Multicentre, Open-label Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection in Children With Severe Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol